期刊
FRONTIERS IN ENDOCRINOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.794437
关键词
oxidized phospholipids; OxPAPC; endothelial barrier; inflammation; lung injury; Rho GTPases; receptor
资金
- National Heart, Lung, and Blood Institute [RO1HL076259, R01HL146829, RO1HL087823]
- National Institute of General Medical Sciences [RO1GM122940]
Previous studies have focused on the pro-inflammatory and barrier disruptive effects of lipid oxidation products in chronic vascular inflammation related to atherosclerosis, but recent evidence suggests that certain oxidized phospholipids actually have barrier protective and anti-inflammatory properties in the lung vascular endothelium. Among these, oxidized 1-palmitoyl-2-arachdonyl-sn-glycero-3-phosphocholine has been shown to enhance endothelial cell barrier properties and protect against vascular permeability induced by various agonists. Additionally, signaling mechanisms involving cytoskeletal remodeling play a significant role in the regulation of endothelial barrier function by oxidized phospholipids.
Earlier studies investigating the pathogenesis of chronic vascular inflammation associated with atherosclerosis described pro-inflammatory and vascular barrier disruptive effects of lipid oxidation products accumulated in the sites of vascular lesion and atherosclerotic plaque. However, accumulating evidence including studies from our group suggests potent barrier protective and anti-inflammatory properties of certain oxidized phospholipids (OxPLs) in the lung vascular endothelium. Among these OxPLs, oxidized 1-palmitoyl-2-arachdonyl-sn-glycero-3-phosphocholine (OxPAPC) causes sustained enhancement of lung endothelial cell (EC) basal barrier properties and protects against vascular permeability induced by a wide variety of agonists ranging from bacterial pathogens and their cell wall components, endotoxins, thrombin, mechanical insults, and inflammatory cytokines. On the other hand, truncated OxPLs cause acute endothelial barrier disruption and potentiate inflammation. It appears that multiple signaling mechanisms triggering cytoskeletal remodeling are involved in OxPLs-mediated regulation of EC barrier. The promising vascular barrier protective and anti-inflammatory properties exhibited by OxPAPC and its particular components that have been established in the cellular and animal models of sepsis and acute lung injury has prompted consideration of OxPAPC as a prototype therapeutic molecule. In this review, we will summarize signaling and cytoskeletal mechanisms involved in OxPLs-mediated damage, rescue, and restoration of endothelial barrier in various pathophysiological settings and discuss a future potential of OxPAPC in treating lung disorders associated with endothelial barrier dysfunction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据